10/19/2005 5:10:27 PM
Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that UK-based ML Laboratories has decided to renew its PER.C6(tm) technology license agreement. Under the renewed agreement, the parties have negotiated research and commercial terms for gene therapy products developed and manufactured on PER.C6(tm) technology. Further details were not disclosed.
comments powered by